Patents Examined by D Margaret M Seaman
  • Patent number: 10562896
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 18, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 10556883
    Abstract: Compounds having formula (I) are described. Also described, are methods of using these compounds to treat diseases, conditions, and disorders.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: February 11, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Gilles Ouvry, Craig Steven Harris, Yushma Bhurruth-Alcor
  • Patent number: 10557853
    Abstract: The present invention is directed to fluorescent molecular sensor based on Thiazole Orange for protein detection. Interaction of the protein target with the molecular sensors of this invention results in a significant increase in the fluorescence emission. The generation of light output signal enables one to detect protein biomarkers associated with different diseases or detecting the protein of interest also in living cells.
    Type: Grant
    Filed: July 2, 2017
    Date of Patent: February 11, 2020
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: David Margulies, Leila Motiei, Linor Unger
  • Patent number: 10550087
    Abstract: Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: February 4, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Jill Marie Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
  • Patent number: 10548889
    Abstract: The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: February 4, 2020
    Assignee: X4 PHARMACEUTICALS, INC.
    Inventor: Karel Marie Joseph Brands
  • Patent number: 10550120
    Abstract: The present invention provides a medicament useful for treatment and/or prevention of cancer, a vaccine adjuvant, and an inhibitor of immune checkpoint comprising a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Bonds a-d, Ring A, R1, R1?, R2, R2?, R3-R8, and n are as defined in the present specification.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: February 4, 2020
    Assignees: TOHOKU UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Haruhisa Kikuchi, Yoshiteru Oshima, Toshio Hattori, Osamu Yamada, Jing Zhang, Shinya Kida, Shinya Murase
  • Patent number: 10550106
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 4, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • Patent number: 10550098
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 4, 2020
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Patent number: 10544125
    Abstract: The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of Al3818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 28, 2020
    Assignee: Advenchen Pharmaceuticals, LLC
    Inventors: Guoqing Paul Chen, Changren Yan
  • Patent number: 10537567
    Abstract: Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 21, 2020
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Joerg Ruschel, Matthew D. Abbinanti, Kenneth M. Rosen, Lisa McKerracher
  • Patent number: 10537565
    Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 21, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Patricia Hurter, William Rowe, Christopher R. Young, Adriana Costache, Patrick R. Connelly, Mariusz Krawiec, Yuchuan Gong, Yushi Feng, Martin Trudeau
  • Patent number: 10533014
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 14, 2020
    Assignee: FLEXUS BIOSCIENCES, INC.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
  • Patent number: 10519123
    Abstract: A process for preparing an aromatic N-glycidylamine comprising a step of heating a mixture of an amine having at least one aromatic aminohydrogen atom with at least 0.7 equivalent of epichlorohydrin per aminohydrogen equivalent of the amine in presence of a catalyst dissolved in an inert organic solvent, at a pressure in a range of 200 mbar to 600 mbar; and adding a base to the mixture at a pressure in a range of 200 mbar to 600 mbar to facilitate dehydrochlorination of product of the previous step to obtain the aromatic N-glycidylamine.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 31, 2019
    Assignee: Grasim Industries Limited
    Inventors: Ashok Kumar Singh, Prashant Samant, Alif Lalani, Mukesh Kathalewar, Vishnu More
  • Patent number: 10501471
    Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof and methods of using the same for treating cardiovascular diseases.
    Type: Grant
    Filed: June 2, 2019
    Date of Patent: December 10, 2019
    Inventor: John Frederick Schmedtje, Jr.
  • Patent number: 10501466
    Abstract: Described are N-(6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-2,3-dihydro-1H-inden-1-yl)benzamide and acetamide-containing compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: December 10, 2019
    Assignee: Vanderbilt University
    Inventors: Stephen W. Fesik, Shaun R. Stauffer, James M. Salovich, William P. Tansey, Feng Wang, Jason Phan, Edward T. Olejniczak
  • Patent number: 10493166
    Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: December 3, 2019
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein
  • Patent number: 10479797
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: November 19, 2019
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Thuy-Anh Tran, Quyen-Quyen Do, Brett Ullman, Anthony C. Blackburn, Maiko Nagura
  • Patent number: 10479765
    Abstract: The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 19, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hartmut Beck, Tobias Thaler, Raimund Kast, Daniel Meibom, Mark Meininghaus, Carsten Terjung, Martina Delbeck, Klemens Lustig, Uwe Muenster, Britta Olenik
  • Patent number: 10464951
    Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: November 5, 2019
    Assignee: INTREXON CORPORATION
    Inventors: Sheela K. Chellappan, Robert E. Hormann, Inna Shulman
  • Patent number: 10464925
    Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: November 5, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Dennis Buckley, Georg Winter